CSIMarket Company Name, Ticker, Customers, else..
 
Biofrontera Inc   (NASDAQ: BFRI)
Other Ticker:  
 
 
Price: $1.0500 $-0.08 -7.080%
Day's High: $1.14 Week Perf: -5.41 %
Day's Low: $ 1.02 30 Day Perf: -11.76 %
Volume (M): 265 52 Wk High: $ 2.43
Volume (M$): $ 278 52 Wk Avg: $1.16
Open: $1.14 52 Wk Low: $0.61



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 6
 Employees 60
 Revenues (TTM) (Millions $) 88
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) -11
 Capital Exp. (TTM) (Millions $) 0

Biofrontera Inc
Biofrontera Inc. is a biopharmaceutical company that focuses on the development and commercialization of dermatological treatments. The company specializes in the area of dermatology, with a particular emphasis on skin cancer and other skin disorders. Biofrontera develops and markets innovative products that aim to improve the lives of patients suffering from these conditions. They have a strong research and development pipeline and are committed to bringing new and effective treatments to market. The company is headquartered in Leverkusen, Germany and operates globally, with a presence in Europe, the United States, and other international markets.


   Company Address: 120 Presidential Way Woburn 1801 MA
   Company Phone Number: 245-1325   Stock Exchange / Ticker: NASDAQ BFRI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EOLS   -7.25%    
MNKD   -2.27%    
PBYI   -12.96%    
RVNC   -2.95%    
TEVA   -2.37%    
VTRS   -2.01%    
• View Complete Report
   



Biofrontera Inc

Investors Beware: Biofrontera Inc Faces Significant Losses and Decline in Stock Amid Impressive Year-to-Date Performance



Biofrontera Inc, a pharmaceutical company listed on NASDAQ, has experienced a decline of -8.98% in its stock over the last five trading days. However, the stock has shown an impressive year-to-date performance of 979.16%, and is currently trading 339.7% above its 52-week average. Analyzing the company's financial results for the April to June 30, 2023 period, some concerning figures emerge. This article aims to outline the facts and consider how they may impact the future of Biofrontera Inc.
1. Significant Shortfall per Share:
Biofrontera Inc's shortfall per share for the April to June 30, 2023 timeframe was $-7.23, in comparison to $-0.05 from the previous year. This represents a significant increase in shortfall, suggesting potential financial challenges. Moreover, there was an advancement in shortfall from the prior reporting season's $-0.28 per share.
Biofrontera Inc

Deepening Losses Reflect Troubling Financial Performance

Biofrontera Inc. is a pharmaceutical company that operates in the United States, Germany, and other European countries. Recently, the company has recorded a deficit per stock of $-0.28 per share, which is a decrease from $0.32 per share a year ago. This indicates that the company has experienced financial struggles, which may be due to a range of reasons - such as increased competition in the market, regulations, or implementation of new policies.
Furthermore, the recorded deficit is an increase from the preceding financial reporting period of $-0.07 per share. This means that the company's financial performance has been deteriorating over time, which could be a cause for concern for shareholders and investors.






Biofrontera Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com